Baxdela generic
Baxdela is an antibiotic drug owned by Melinta. It contains the active ingredient delafloxacin meglumine and was first authorized for market use on June 19, 2017. The drug holds a total of 13 patents, none of which have expired yet.
When will Baxdela generic be available?
The drug patents for Baxdela will start to face challenges from June 19, 2026. The generic versions of Baxdela are projected to be available after February 27, 2033, marking the expiry date of the last patent associated with the drug.
Baxdela uses
Baxdela is used in the treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults. It is available in powder and intravenous dosage forms.
Baxdela patent expiration
Baxdela holds a total of 13 drug patents. None of these patents have yet expired, and the last one is due for expiry on February 27, 2033. This will also prompt the release of Baxdela generic versions. Below are the details of the patents: